The U.S. Meals and Drug Administration (FDA) accepted a brand new drug utility (NDA) for zidesamtinib, an investigational ROS1-selective inhibitor meant for adults with regionally superior or metastatic ROS1-positive non-small cell lung most cancers (NSCLC) who beforehand obtained no less than one ROS1 tyrosine kinase inhibitor (TKI), in accordance with a information launch from Nuvalent, Inc.
The regulatory company set a prescription drug consumer price act (PDUFA) goal motion date of Sept. 18, 2026.
Based on the FDA’s web site, an NDA is a request an organization sends to the FDA asking for approval to make a brand new remedy accessible to sufferers in the US, supported by all of the analysis displaying it’s protected and efficient. Furthermore, the web site explains {that a} PDUFA goal motion date is the deadline by which the FDA should resolve whether or not to approve an organization’s NDA.
The NDA depends on findings from TKI pre-treated sufferers enrolled within the international part 1/2 ARROS-1 medical trial. Nuvalent additionally reported preliminary knowledge from the continued TKI-naïve cohort, with each knowledge units offered through the Presidential Symposium on the IASLC 2025 World Convention on Lung Most cancers.
Zidesamtinib was created to handle limitations seen with presently accessible ROS1 inhibitors, significantly resistance that may happen by means of treatment-emergent mutations reminiscent of G2032R. The remedy is designed for mind penetrance to assist sufferers who develop central nervous system (CNS) metastases, and to keep away from inhibiting the tropomyosin receptor kinase (TRK) household, which can restrict TRK-related unwanted effects.
The investigational remedy has obtained breakthrough remedy designation for sufferers with metastatic ROS1-positive NSCLC beforehand handled with two or extra ROS1 TKIs, in addition to orphan drug designation for ROS1-positive NSCLC.
Section 1/2 ARROS-1 Trial Information Spotlight Notable Response Charges in Sufferers with Lung Most cancers
Amongst sufferers beforehand handled with both Xalkori (crizotinib) or Rozlytrek (entrectinib), the ORR reached 51% with a CR charge of two%. Sufferers who had solely obtained Xalkori achieved an ORR of 68%, whereas those that beforehand obtained solely Rozlytrek had an ORR of 33%.
Responses occurred even in people handled with no less than two prior ROS1 TKIs, attaining an ORR of 38%. Sufferers uncovered to Augtyro (repotrectinib) skilled an ORR of 47%, with period of response (DOR) starting from roughly 3.5 months to 17.2 months. Those that had obtained Ibtrozi (taletrectinib) demonstrated an ORR of 43%, with DOR starting from roughly 5.2 months to greater than seven months.
The ARROS-1 trial, a world first-in-human research, evaluated zidesamtinib throughout a number of dose ranges within the part 1 portion. The part 2 portion makes use of a 100-mg once-daily really useful dose for each TKI-naïve and TKI pre-treated sufferers.
“Within the pivotal dataset for TKI pretreated sufferers with superior ROS1-positive NSCLC, zidesamtinib demonstrated a medical profile in keeping with its preclinical design targets,” Dr. Alexander E. Drilon stated through the presentation of knowledge on the IASLC 2025 World Convention on Lung Most cancers. “[We saw] sturdy exercise, together with in closely pretreated sufferers who’ve exhausted accessible choices, together with prior [Augtyro] and [Ibtrozi], and sufferers with the ROS1 G2032R resistance mutation.”
Drilon is chief of the Early Drug Improvement Service at Memorial Sloan Kettering Most cancers Heart in New York.
References
- “Nuvalent Broadcasts FDA Acceptance of New Drug Software for Zidesamtinib for the Therapy of TKI Pre-treated Sufferers with Superior ROS1-positive NSCLC,” by Nuvalent, Inc. Information launch; Nov. 19, 2025.
- “New Drug Software (NDA),” by the U.S. FDA. Information launch; Jan. 21, 2022.
- “Zidesamtinib Elicits Responses in ROS1-Optimistic NSCLC,” by Caroline Seymour. CURE; Sept. 9, 2025. https://www.curetoday.com/view/zidesamtinib-elicits-responses-in-ros1-positive-nsclc
For extra information on most cancers updates, analysis and training, don’t neglect to
